Introduction
Studies of IgGIA subclass antibody responses in viral infections of man and in other conditions have been encouraged by the availability of monoclonal antibodies to these subclasses. IgGl antibodies comprise 60-70% of the total IgG in adults. Antibodies active against polysaccharide antigensmainly IgG2 (30% of total 1gG)-rise slowly with age (Schur et al., 1979) and IgGz deficiencies have been linked with susceptibility to infection by bacteria with polysaccharide capsules (Oxelius, 1984) . Often, however, there is a co-existing deficiency in IgG4 (Heiner, 1984) , a subclass comprising 4% of the total IgG that does not fix complement but that has been associated with allergic conditions. There have been a few studies of the subclass distribution of antibodies to viruses, including that of Sundqvist et al. (1984) on herpes simplex and varicella-zoster and three studies on rubella. Skvaril and Schilt (1984) used monoclonal antibodies to show that antibodies in immune individuals were almost exclusively IgGI. Both Doerr et al. (1984) and Beck (1981) , however, using either polyclonal antibodies or density gradient separation for identification of IgG subclasses, had reported that rubella-specific IgG3 (normally 6% of the total IgG) was present in both acute-and immune-phase sera. Rubella-specific IgA responses have been described (A1 Halonen et al., 1979) but their subclass distribution has not been reported. We therefore examined rubella antibodies in sera from immune subjects and from recently infected patients. Received 24 Apr. 1985; accepted 19 June 1985. 
Materials and Methods

Sera
The following rubella antibody-positive sera were studied: (1) single samples from 21 adult immune patients with rheumatoid or seronegative arthritis (Mims et al., 1985) ; (2) successive samples taken 7 weeks and later after rubella vaccination (RA27 or Cendehill) from 10 individuals with joint complications; (3) single samples from six naturally infected individuals taken 1-10 days after the appearance of the rash; (4) successive samples from six naturally infected individuals taken 5 days-2 years after infection; (5) cord-blood sera from two and non-cord sera from eight congenitally infected infants. Serum series 2-5 were very kindly provided by Dr Jennifer Best, St Thomas's Hospital, London. Synovial fluid samples from the 21 patients with arthritis were also tested.
Antibody titrations
Rubella spec@ IgG subclass antibodies. A micro-ELISA system was employed. Dynatech M 12GA micro-ELISA plates coated with rubella HA1 antigen diluted 1 00-fold (produced from infected BHK2 1 cells; Wellcome Laboratories, Beckenham, Kent) were allowed to react with test fluids diluted 100-fold, and then with monoclonal antibodies to human IgG subclasses 1, 2, 3 and 4 (Seward Laboratory, Bedford; clone nos. NLl6, GOM 1, ZG4 and RJ4) diluted 1 in 1600 (anti IgG,), 400 (anti IgG2 and anti IgG4) and 200 (anti IgG3). Finally, horseradish peroxidase-conjugated rabbit an ti-mouse immunoglo bulin (Dakopatts) diluted 1 in 800, was added, followed by the substrate o-phenylene diamine (BDH). After incubation in the dark for 30 min the reaction was terminated by adding 4~ HzS04 and the OD read at 492 nm. The OD reading obtained with plates coated with negative antigen control (Wellcome) was then subtracted from the test reading to give the specific OD value. The optimal dilutions of antigen, test fluids, monoclonal antibodies and conjugates were determined after preliminary checkerboard titrations. Throughout the procedure, PBS Tween (0.05%) was used as a diluent and washing agent. The ELISA method was also used to obtain an end point titration of antibodies to rubella by determining the final serum dilution that gave an OD reading at least 0-2 units higher than the control value.
Rubella-specijic IgA subclass antibodies. The same method was used with monoclonal antibodies to human IgAl and IgAz (Seward Laboratory; clone nos NIF2 and 2E2) diluted 1 in 400 and 1600 respectively. In these tests the antigen-coated wells were treated with 1% bovine serum albumen (BSA) for 2 h at 37"C, and 1% BSA was added to the conjugate.
Haemagglutination inhibiting (HAI) and single radial haemolysis (SRH) antibody determinations. Rubella haemagglutinating antigen (HA) was obtained from Wellcome Laboratories and HA1 antibody titrations were performed in V-well microtitration plates (Sterilin, Teddington, Middlesex). For SRH, "Rubascreen" SRH plates (Northumbria Biologicals, Cramlington, Northumberland) were used; the diameters of the haemolytic zones were recorded and the zone areas calculated. The areas plotted against log2 HA1 antibody titres for all sera gave a straight line relationship.
Results
In all patients' sera, IgGl antibody was the major subclass detected and it was generally present in proportion to the rubella HA1 antibody titre. A linear relationship was shown between the loglo specific absorbance and the log2 of the HA1 titre of sera from the 21 patients with chronic arthritis, with a Spearman's rank correlation coefficient of 0.77 (figure). ELISA titrations were performed with sera In the sequential sera taken after natural infection or vaccination, the earliest IgG antibody detectable, 10 days after the rash, was IgGI. This remained the only type of IgG antibody detected in all these patients; the levels rose during 6 months, but not always in parallel with the rise in HA1 and SRH antibody titres. Sera from two of the patients also showed a small amount of rubella-specific IgG4. These patients had high HA1 antibody titres (1280 and 10 240) but in eight others with equally high HA1 antibody titres, IgG4 was not detected. At no time was rubella-specific IgG2 or IgG3 detected. The single and sequential serum samples from naturally infected individuals (groups 3 and 4) were also tested for rubella-specific IgA responses. IgA antibody was detected in serum from six of the 12 patients as early as 3 days and up to 28 days after the onset of the rash, but not in three of these patients from whom serum was available after 3-24 months. IgA2 antibody was not detected.
Synovial fluids from the 21 patients with arthritis were also tested, and in two of them there was evidence for the synthesis of rubella antibody in the affected joint (Mims et al., 1985) . In all these synovial fluids, IgGl was the only rubella-specific antibody detected. Of the congenitally infected group, both cord sera and four of the post-natal sera contained rubella-specific IgGl antibodies; the remaining four gave high positive results with control (virus negative) antigen, and were not tested further.
Discussion
The pattern of the IgG subclass response to most virus infections is not known. Indeed, the biological significance of these different antibodies is obscure. Our results, however, confirm the findings of Skvaril and Schilt (1 984) that in immune individuals rubella specific antibodies are virtually confined to the IgGl subclass. They also show that even in the earliest stages of the antibody response, IgGl is the principle type of IgG antibody. In many of the sera studied, rubella HA1 and SRH titres were high so that the other subclasses, if represented in proportion to their total content in serum, would have been detected. The only one detected, however, was IgG4. Although rubella-specific IgG4 was found in two sera, it was not present in eight others with equally high HA1 titres ( 3 1280).
In the 21 synovial fluids tested, IgGl was the only rubella-specific antibody detected, i.e., there was no evidence for the synthesis of other subclasses of antibody in the inflamed joints of patients with rheumatoid or seronegative arthritis.
The rubella-specific IgA tests on sequential sera suggested that the IgA response is detectable before the IgG response. Not unexpectedly, it is confined to the IgAl subclass. The IgA2 subclass normally comprises <20% of serum IgA, but is present in
